Taylor & Francis Group
Browse

Acute kidney injury in group A streptococcal bacteraemia: incidence, outcome and predictive value of C-reactive protein

Download (33.79 kB)
journal contribution
posted on 2022-09-01, 11:20 authored by Johanna Vilhonen, Niina Koivuviita, Tero Vahlberg, Jaana Vuopio, Jarmo Oksi

A ubiquitous human pathogen, Streptococcus pyogenes (Group A Streptococcus, GAS) causes infections from mild pharyngitis to severe septic infections. Acute kidney injury (AKI) is a condition of prompt decline of renal function. The aim of the present study was to report the incidence and outcome of AKI in GAS bacteraemia and to evaluate the diagnostic value of serum C-reactive protein as an indicator of AKI.

All adult patients with GAS bacteraemia treated at Turku University Hospital from 2007 to 2018 were identified and their patient records were scrutinised.

Of 195 included patients, 38 (19.5%) had AKI stage 1, 20 (10.3%) AKI stage 2 and 26 (13.3%) AKI stage 3 and 111 (56.9%) did not have AKI. The adjusted seven-day mortality was significantly higher in AKI stages 2 and 3 compared to the non-AKI group (15% and 19% vs. 3.6%; p = .046 and .006, respectively). Of the survivors, 95.8% met the criteria of renal recovery at discharge. The higher the AKI stage, the higher was the mean serum CRP level on admission. The optimal cut-off for CRP to identify patients with AKI stage 2 or 3 was ≥244 mg/l (sensitivity 82.6% and specificity 75.8%).

AKI is common in patients with GAS bacteraemia and the severity of AKI correlates with the CRP level on admission. The mortality of patients with GAS bacteraemia and AKI is significantly higher than of patients without AKI. Most survivors, however, show renal recovery.

AKI is common in group A Streptococcal bacteraemia and increases mortality compared to bacteraemia alone. However, renal recovery is also common. A high CRP level on admission correlates significantly positively with the degree of severity of AKI.

Funding

This work was supported by the Maud Kuistila Foundation under grant number 2018-0063 F; by the Finnish Medical Foundation under grant number 2018-2136; by the Rauno ja Anne Puolimatka Foundation (2017 and 2020); by Competitive State Financing of the Expert Responsibility area of the Turku University Hospital under grant number 11162 and the Finnish Infectious Disease Association (2020).

History

Usage metrics

    Infectious Diseases

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC